secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001104659-24-071070
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants pediatric exclusivity for Nucynta franchise; exclusivity extended to Jan 2027
--------------------------------------------------------------------------------

- FDA granted pediatric exclusivity for Nucynta and Nucynta ER; Nucynta exclusivity now to Jan 3, 2027, Nucynta ER to Dec 27, 2025.
- Pediatric exclusivity adds six months on top of previously granted New Patient Population exclusivity (granted 2023).
- Collegium CMO Thomas Smith said the grant enhances the value of the Nucynta franchise and bolsters near-term outlook.
- Nucynta is approved for acute pain in adults and pediatric patients 6+; Nucynta ER for severe pain and diabetic peripheral neuropathy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924071070/0001104659-24-071070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000110465924071070/tm2417144d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer